Newsletter | September 24, 2025

09.24.25 -- What's Next In Gene Therapy: AI, rAAV, And Regulatory Affairs

AI For Faster, Smarter Gene Therapy Development And Manufacturing

Through real-world case studies, we highlight how AI-driven tools enhance efficiency, quality, and scalability, while also addressing the challenges, infrastructure requirements, and organizational mindset needed for successful implementation.

 

Scalability And Productivity Of Transient Transfection AAV Production

By thoroughly understanding a process and its components, adopting robust controls, utilizing appropriate analytical techniques, and working closely with partners and experts, organizations can overcome challenges and achieve their goals for scaling rAAV.

 

Boosting CMC Regulatory Efficiency In Gene Therapy

Ensure your business stays ahead in today’s complex environment by practicing regulatory affairs strategies that streamline compliance and product approvals. By proactively navigating evolving regulations, you can accelerate time-to-market and secure long-term success.

 

OPCU VIDEO FEATURE

Viralgen Capacity Update July 2025: Cell & Gene Therapy

As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.